Brazil issues reminder on import licensing:
This article was originally published in Clinica
The Brazilian health surveillance agency, Anvisa, has issued a reminder that all imported healthcare products for use in research and clinical trials must receive an import licence before they leave the country of origin. The regulations, set out in Article 62 of Resolution RDC-01 of January 6 2003, seek to ensure that the handling and storage of such products is subject to the quality control criteria of the manufacturer.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.